Therefore, we aimed to explore the potential imaging characteristics of the main tumor and intra-thoracic findings, as well as metastases and infiltration patterns, among patients with advanced-stage (stage IIIB–IV) lung adenocarcinoma and driver mutations in EGFR, KRAS, or ALK. This evidence concerns the gene KRAS and lung adenocarcinoma.